RxDoctor Payments Data

Elie Schochet, MD

Colon & Rectal Surgery · Ft Lauderdale, FLNPI 1841463130

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $59,693 of the $95,906 with a category attached, or 62.2%. Napo Pharmaceuticals Inc accounts for 63.5% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2023 at $40,446 and has fallen 99.1% since, to $375 in 2025. Among colon & rectal surgery clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$95,906in general payments, 2019–2025

Across 167 payments — averaging $574.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Napo Pharmaceuticals Inc$61K
  • Intuitive Surgical$30K
  • TELA Bio, Inc.$2K
  • THD America, Inc.$1K
  • Medical Device Business Services, Inc.$227
  • Biom'up SA$196
  • plus $758 from 7 others

What the payments were for

  • Speaking & faculty fees$59,69362%
  • Travel & lodging$3,1613%
  • Food & beverage$5,5416%
  • Education$27,50029%
  • Gifts$110%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$95,906 in reported general payments places this provider in the 90th percentile of 157 colon & rectal surgery providers in Florida.

See all colon & rectal surgery providers in Florida

Medicare billing

Part B allowed, 2024
$44,220
Medicare patients
115
Services billed
326

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MytesiCrofelemer30$74,988
Acyclovir11$635

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Napo Pharmaceuticals IncMytesi$60,942$74,98830 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 157 colon & rectal surgery providers in Florida.

Other colon & rectal surgery in Ft Lauderdale

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →